UCSF

Kelonia Therapeutics Appoints Kristen Hege, M.D., and Mathai Mammen, M.D., Ph.D., to Board of Directors

Retrieved on: 
Thursday, March 28, 2024
Biotechnology, Health, Genetics, Pharmaceutical, Oncology, Harvard Medical School, Flexner Report, Organization, Bone marrow, Internal medicine, UCSF, Hematology, Science, HST, Massachusetts Institute of Technology, BCMA, Patient, HIV, Dartmouth College, BMS, Cancer, Bristol Myers Squibb, Doctor of Philosophy, Daratumumab, Biochemistry, Chemistry, Therapy, Harvard University, Hospital, Johnson & Johnson, Drug development, FDA, Pharmaceutical industry

Kelonia Therapeutics , a biotech company revolutionizing in vivo gene delivery, today announced the appointments of global leaders in cell therapy and drug development, Kristen Hege, M.D., and Mathai Mammen, M.D., Ph.D., to its board of directors.

Key Points: 
  • Kelonia Therapeutics , a biotech company revolutionizing in vivo gene delivery, today announced the appointments of global leaders in cell therapy and drug development, Kristen Hege, M.D., and Mathai Mammen, M.D., Ph.D., to its board of directors.
  • Furthermore, some patients never receive their autologous CAR-T products due to disease progression or clinical deterioration during the manufacturing window.
  • In addition, the field of cell and gene therapy has gained tremendous expertise and insight into the manufacturing of lentiviral vectors at commercial scale.
  • from the Harvard Medical School and Massachusetts Institute of Technology (HST) and a Ph.D. in chemistry from Harvard University.

Breakout Ventures Welcomes Five New Venture Partners

Retrieved on: 
Tuesday, March 26, 2024
Biotechnology, Health, Finance, Pharmaceutical, Professional Services, Other Science, Research, Medical Devices, Start-Up, Data Analytics, Genetics, Health Technology, Science, Clinical Trials, HTP, Genomics, University of Cambridge, Ashland Global, UCSF, Data science, Twist Bioscience, Walter, MIT, Synthetic biology, Cell biology, UC, University, Software, Doctor of Philosophy, Elemental Machines, University of Michigan, Marshall Scholarship, Pleasure, Silicon, Biochemistry, Investment, Therapy, Ilan, Drug development, Multimedia, Coco, University of California, Berkeley, Management

Breakout Ventures , the home for creative bioscience entrepreneurs, is pleased to welcome five new venture partners.

Key Points: 
  • Breakout Ventures , the home for creative bioscience entrepreneurs, is pleased to welcome five new venture partners.
  • Walter advises numerous portfolio companies of VC and PE firms, including as a board member for Checkerspot, a Breakout Ventures investment.
  • Breakout supports our portfolio companies with more than just capital, and we are excited to welcome this group of insightful leaders.
  • To learn more about Breakout Ventures, visit: https://www.breakout.vc/ .

Sophia Tao joins The Hassell Law Group as Associate Attorney in our San Francisco Office

Retrieved on: 
Wednesday, April 3, 2024
Tao, Research, Scientist, Innovation, UCSF, Associate, Partnership, SAN, Public policy, University, Accident, Writing, File, Hastings Constitutional Law Quarterly, Private law, Associate attorney, Practice of law

SAN FRANCISCO, April 3, 2024 /PRNewswire-PRWeb/ -- The Hassell Law Group, an award-winning personal injury law firm known for its dedication to recovering compensation for those injured by the negligence of others, is pleased to announce the addition of Sophia Tao to its team as an Associate Attorney. Sophia joined the firm in 2023 while awaiting her California Bar exam results and was officially admitted to practice law in California in December of the same year.

Key Points: 
  • SAN FRANCISCO, April 3, 2024 /PRNewswire-PRWeb/ -- The Hassell Law Group , an award-winning personal injury law firm known for its dedication to recovering compensation for those injured by the negligence of others, is pleased to announce the addition of Sophia Tao to its team as an Associate Attorney.
  • Before joining The Hassell Law Group, she worked as a paralegal at a renowned San Francisco personal injury law firm, where she honed her skills in filing pleadings, managing trial motions, and organizing discovery responses.
  • Since joining The Hassell Law Group, Sophia has quickly become an invaluable asset to the firm's legal team, working directly under the guidance of our senior attorneys.
  • The Hassell Law Group welcomes Sophia Tao and looks forward to her contributions in providing exceptional legal representation to individuals and families affected by personal injuries.

AEOVIAN PHARMACEUTICALS DOSES FIRST PARTICIPANTS IN PHASE 1 CLINICAL TRIAL, STRENGTHENS LEADERSHIP TEAM AND RAISES ADDITIONAL $50 MILLION FINANCING

Retrieved on: 
Thursday, March 28, 2024
Xenon, TSC, Epilepsy, Alexion Pharmaceuticals, Patient, Sale, Investment, Therapy, Melinda French Gates, Jazz Pharmaceuticals, Genetic disorder, Ageing, CIO, Notifiable disease, Biotechnology, Yale University, CNS, NIH, Zajac, University of Bristol, Honours degree, UCSF, Drug discovery, Evotec, GW Pharmaceuticals, Genetic distance, DSM-IV codes, Wesleyan University, Growth, CFO, BIO, Record, Bachelor of Science, Morgan Stanley, Former, Pharmaceutical industry

BERKELEY, Calif., March 28, 2024 /PRNewswire/ -- Aeovian Pharmaceuticals, a clinical-stage biopharmaceutical company developing novel and highly selective therapeutics that potently inhibit the mTORC1 pathway, today announced that it has dosed the first cohort of participants in a Phase 1 clinical trial for its lead development candidate AV078, a first-in-class CNS penetrant selective mTORC1 inhibitor. Supporting this transition into the clinic, the company has also expanded its leadership team with the appointment of seasoned industry veterans William Greene, M.D., Chief Investment Officer at Hevolution, and Justin Gover, former Chief Executive Officer of GW Pharmaceuticals, to the company's Board of Directors, and appointed Micah Zajic as Chief Financial Officer. The company also recently completed a $50 million financing, led by Hevolution.

Key Points: 
  • Aeovian has assembled a compelling platform for the development of selective mTORC1 inhibitors," said Dr. Greene, CIO at Hevolution.
  • In the $50M financing, Hevolution was joined by existing investors Apollo Health Ventures, Sofinnova Investments, venBio, Evotec and b2venture.
  • This financing will support the completion of the Phase 1 clinical trial in healthy volunteers and prepare for the start of a subsequent Phase 2 clinical trial in adult and pediatric patients with TSC refractory epilepsy.
  • As CEO, he built and led Iconic Therapeutics through discovery, clinical development, and venture financing, which culminated in a successful sale of the company.

New Legislation Aims to Put Future Of Bay Area Transportation in Voters' Hands

Retrieved on: 
Tuesday, March 19, 2024
UCSF, Walking, Transport, MTC, Pedestrian, SAN, Travel, City, Metropolitan Transit Commission, Student, Commission, Housing, Multimedia, Senate, State, Legislation

SAN FRANCISCO, March 19, 2024 /PRNewswire/ -- State Senator Scott Wiener of San Francisco this week joined with State Senator Aisha Wahab of Hayward to jointly author a bill that would allow voters throughout the Bay Area to consider as early as November 2026 a comprehensive transportation revenue and reform measure that would preserve and enhance public transit operations, improve the condition of local streets and roads, and promote mobility and access for all people, including pedestrians, bicyclists and scooter and wheelchair users.

Key Points: 
  • "Our public transportation agencies are struggling to maintain service levels and riders increasingly are asking for reforms to modernize and integrate these systems.
  • SB 1031 also would allow employers with more than 50 workers in the Bay Area to meet the requirements of the Bay Area Commuter Benefits program by providing their employees a regional transit pass.
  • The Clipper BayPass pilot is designed to measure how an all-system pass could impact travel in the Bay Area.
  • MTC is the transportation planning, financing and coordinating agency for the nine-county San Francisco Bay Area.

Bristol Myers Squibb Announces New Data from the Long-Term DAYBREAK Study Reinforcing Efficacy and Safety of Zeposia (ozanimod) in Patients with Relapsing Forms of Multiple Sclerosis

Retrieved on: 
Thursday, February 29, 2024
Biotechnology, Pharmaceutical, Health, UCSF, Master of Science, BMY, MAS, Research, Doctor of Philosophy, Headache, Month, Upper respiratory tract infection, Treatment, COVID-19, Risk, Common, Bristol Myers Squibb, Multiple sclerosis, Safety, University, Neurology, Disability, Abstract, Patient, Disease, Observational study, Poster, Circulatory system, Pharmaceutical industry

Bristol Myers Squibb (NYSE: BMY) today announced new results from the Phase 3 DAYBREAK open-label extension trial, demonstrating the long-term efficacy and safety profile of Zeposia (ozanimod) in patients with relapsing forms of multiple sclerosis (MS).

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) today announced new results from the Phase 3 DAYBREAK open-label extension trial, demonstrating the long-term efficacy and safety profile of Zeposia (ozanimod) in patients with relapsing forms of multiple sclerosis (MS).
  • In the DAYBREAK long-term extension study, treatment with Zeposia demonstrated a low annualized relapse rate of 0.098.
  • Three- and six-month confirmed disability progression was absent in 82.8% and 84.8% of participants in the trial respectively.
  • No new safety signals emerged; data from this long-term observational study of patients treated for up to 81.5 months were consistent with the established safety profile of Zeposia.

Allen Institute joins the Weill Neurohub

Retrieved on: 
Wednesday, March 6, 2024
Engineering, UCSF, Head, Nervous system, Helen Wills Neuroscience Institute, AI, Neurology, Stroke, DSM-IV codes, Faculty, University, Cell biology, UC, Chronic pain, Organization, Knowledge, Disease, Genomics, Science, Biology, Brain, Research, Allen Institute, University of California, Berkeley, Partnership, Pharmaceutical industry

SEATTLE, March 6, 2024 /PRNewswire/ -- The Allen Institute has officially become the newest member of the Weill Neurohub, a collaborative research network advancing treatments for neurological diseases. 

Key Points: 
  • SEATTLE, March 6, 2024 /PRNewswire/ -- The Allen Institute has officially become the newest member of the Weill Neurohub , a collaborative research network advancing treatments for neurological diseases.
  • Founded in 2003 by philanthropist Paul G. Allen, the Allen Institute focuses on big questions in biology through a team-based, open science approach, and currently has moonshot projects in neuroscience, cell biology, and immunology institutes.
  • "The expansion of the Weill Neurohub and our formal partnership with the Allen Institute represents a powerful joining of forces in neuroscience," said Stephen Hauser, M.D., the Robert A. Fishman Distinguished Professor of Neurology at UCSF and director of the UCSF Weill Institute for Neurosciences.
  • These collaborative sessions are intended to spark new joint projects and residencies, focusing on the scientific pillars of the Weill Neurohub.

Transformative Gift from Salesforce Chair and CEO Marc Benioff and Lynne Benioff Will Expand Access and Continuity of Healthcare in Hawai'i

Retrieved on: 
Tuesday, March 5, 2024
UCSF, SAN, HELP, Hospital, Philosophy, Education, Partnership, Health, Burn, Community hospital, Straub Medical Center, Patient, Family, Queen, MBBS, UCSF Medical Center, Neurology

SAN FRANCISCO, March 5, 2024 /PRNewswire/ -- A major donation by longstanding philanthropists in Hawai'i will significantly increase healthcare access, addressing critical infrastructure gaps and helping ensure excellent and continuous care for communities in Hawai'i.

Key Points: 
  • The $150 million gift by Marc and Lynne Benioff is one of the largest single private donations in Hawai'i's history.
  • It provides $100 million for Hawai'i Pacific Health, one of the state's largest nonprofit healthcare organizations, to help create a "healthcare campus of the future" at Honolulu-based Straub Medical Center.
  • "Hilo Medical Center's mission is to provide the best possible healthcare for our family, friends and neighbors," says Dan Brinkman, CEO of Hilo Medical Center.
  • "We are truly grateful for this extremely generous and transformational gift," said Ray Vara, president and CEO of Hawai'i Pacific Health.

Open Call to Cerner Health Systems: End-to-End Cerner Integrations Now Available with Ambience Healthcare

Retrieved on: 
Tuesday, March 5, 2024
UCSF, SAN, Oracle, EMR, Caregiver, AI, Memorial Hermann Health System, Language, EHR, CDI, Emergency medicine, Learning, Conference, Documentation, CPT, Patient, Medical device

SAN FRANCISCO, March 5, 2024 /PRNewswire/ -- Ambience Healthcare , the most comprehensive AI operating system for healthcare organizations, has announced a full integration with Oracle's Cerner Millennium Electronic Health Record (EHR).

Key Points: 
  • SAN FRANCISCO, March 5, 2024 /PRNewswire/ -- Ambience Healthcare , the most comprehensive AI operating system for healthcare organizations, has announced a full integration with Oracle's Cerner Millennium Electronic Health Record (EHR).
  • With a native workflow integration into DynDoc, clinicians can leverage their normal workflows to edit their notes section-by-section in Cerner.
  • With this update, Ambience Healthcare is now the only AI solution with end-to-end integrations across Cerner and Epic EHRs.
  • Ambience Healthcare's AI operating system has been deployed at UCSF, Memorial Hermann Health System, John Muir Health, The Oncology Institute, and Eventus WholeHealth.

UCSF Rosenman Institute Awards 2023 ADAPT to Innovative Healthcare Startups Neura Health and ThriveLink

Retrieved on: 
Tuesday, February 27, 2024
UCSF, SAN, Neuroscience Research Australia, Senior, ADAPT, MD, Health, Blue Shield, Neurology, Food, School, Corporate development, Patient, Rosenman, Corporation, Housing, Partnership, Pharmaceutical industry

SAN FRANCISCO, Feb. 27, 2024 /PRNewswire/ -- The UCSF Rosenman Institute announces Neura Health and ThriveLink as the recipients of the 2023 UCSF Rosenman ADAPT program (ADAPT) awards. This marks a significant achievement in healthcare innovation, accelerating the development of telehealth and AI-driven healthcare solutions that address healthcare delivery and equity.

Key Points: 
  • SAN FRANCISCO, Feb. 27, 2024 /PRNewswire/ -- The UCSF Rosenman Institute announces Neura Health and ThriveLink as the recipients of the 2023 UCSF Rosenman ADAPT program (ADAPT) awards.
  • This marks a significant achievement in healthcare innovation, accelerating the development of telehealth and AI-driven healthcare solutions that address healthcare delivery and equity.
  • Neura Health and ThriveLink will each receive $100,000 in non-dilutive funding and have the unique opportunity to collaborate with ADAPT program partners.
  • Christine Winoto, Executive Director of the UCSF Rosenman Institute, underscores the impact of the ADAPT program: "This initiative is not just an award; it's a catalyst bringing together agile healthcare startups and established companies.